Sylvie Gazzeri

Dr. Sylvie Gazzeri

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2018 in Cancer Letters
Verified
Journal Article
Closed access
MGMarie Guerard
Marie Guerard
TRThomas Robin
Thomas Robin
PPPascal Perron
Pascal Perron
AHAnne-Sophie Hatat
Anne-Sophie Hatat
LDLaurence David-Boudet
Laurence David-Boudet
SGSylvie Gazzeri
Sylvie Gazzeri

26 October 2018 in Biologie Aujourd'hui
Verified
Journal Article
Closed access
SGSylvie Gazzeri
Sylvie Gazzeri
L’EGFR (Epidermal Growth Factor Receptor) est l’une des molécules les plus étudiées en biologie. Depuis son identification précoce et son clonage jusqu’à la découverte de son rôle dans le cancer, ces analyses ont été à la pointe de notre compréhension des récepteurs à activité tyrosine kinase et des signaux cellulaires qui médient l’homéostasie, mais qui, une fois surexprimés, facilitent la tumorigenèse. Si les fonctions biologiques de l’EGFR impliquent traditionnellement l’activation d’un réseau de signalisation à partir de la membrane plasmique, un autre mode de signalisation de l’EGFR a été mis en évidence dans lequel l’EGFR est transporté après endocytose de la surface cellulaire vers le noyau, où il agit comme régulateur transcriptionnel, transmet des signaux et intervient dans de multiples fonctions biologiques, notamment la prolifération cellulaire, la progression tumorale, la réparation et la réplication de l’ADN et la résistance aux thérapies anti-cancéreuses. Dans cette revue nous résumerons les connaissances actuelles sur le réseau de signalisation nucléaire de l’EGFR, en nous attachant à son acheminement au noyau, ses fonctions dans le noyau et à l’influence de celles-ci sur la progression du cancer, la survie et la réponse au traitement. EGFR (Epidermal Growth Factor Receptor) is one of the most studied molecules in biology. From its early identification and cloning to the discovery of its role in cancer, it has been at the forefront of our understanding of Receptor Tyrosine Kinase (RTK) and cell signals that induce homeostasis, but when overexpressed, facilitate tumorigenesis. While the biological functions of EGFR traditionally involve the activation of a signaling network from the plasma membrane that includes activation of the RAS/MAPK/ERK, PI3K/AKT and STATS pathways, a new mode of EGFR signaling has been progressively decoded in which membrane-associated EGFR is transported after endocytosis from cell surface to the nucleus through endocytosis, retrograde trafficking to the Golgi, the endoplasmic reticulum and the inner nuclear membrane through a series of proteic interactions. In the nucleus, EGFR acts as a transcriptional regulator, a kinase and a physical interactor, transmits signals and is involved in multiple biological functions, including cell proliferation, tumor progression, DNA repair and replication, and resistance to cancer therapies. In this review, we will summarize current knowledge of the EGFR nuclear signaling network, including how it is delivered to the nucleus, the functions it serves in the nucleus and how these functions affect cancer progression, survival and the response to treatment.

30 August 2022 in Molecular Oncology
Verified
Journal Article
Open access
AHAnne‐Sophie Hatat
Anne‐Sophie Hatat
CBClara Benoit‐Pilven
Clara Benoit‐Pilven
APAmélie Pucciarelli
Amélie Pucciarelli
FFFlorence de Fraipont
Florence de Fraipont
LLLucie Lamothe
Lucie Lamothe
SGSylvie Gazzeri
Sylvie Gazzeri
Despite the initial efficacy of using tyrosine kinase inhibitors of epidermal growth factor receptors (EGFR‐TKIs) for treating patients with non‐small cell lung cancer (NSCLC), resistance inevitably develops. Recent studies highlight a link between alternative splicing and cancer drug response. Therefore, we aimed to identify deregulated splicing events that play a role in resistance to EGFR‐TKI. By using RNA sequencing, reverse‐transcription PCR (RT‐PCR), and RNA interference, we showed that overexpression of a splice variant of the autophagic gene ATG16‐L1 that retains exon 8 and encodes the β‐isoform of autophagy‐related protein 16‐1 (ATG16‐L1 β) concurs acquired resistance to EGFR‐TKI in NSCLC cells. Using matched biopsies, we found increased levels of ATG16‐L1 β at the time of progression in 3 of 11 NSCLC patients treated with EGFR‐TKI. Mechanistically, gefitinib‐induced autophagy was impaired in resistant cells that accumulated ATG16‐L1 β. Neutralization of ATG16‐L1 β restored autophagy in response to gefitinib, induced apoptosis, and inhibited the growth of in ovo tumor xenografts. Conversely, overexpression of ATG16‐L1 β in parental sensitive cells prevented gefitinib‐induced autophagy and increased cell survival. These results support a role of defective autophagy in acquired resistance to EGFR‐TKIs and identify splicing regulation of ATG16‐L1 as a therapeutic vulnerability that could be explored for improving EGFR‐targeted cancer therapy.

2 April 2025 in NAR Cancer
Verified
Journal Article
Open access
MKManal Khalife
Manal Khalife
TJTao Jia
Tao Jia
PCPierre Caron
Pierre Caron
ASAmani Shreim
Amani Shreim
AGAurelie Genoux
Aurelie Genoux
BEBeatrice Eymin
Beatrice Eymin
SRSF2 (serine/arginine-rich splicing factor 2) is a critical regulator of pre-messenger RNA splicing, which also plays noncanonical functions in transcription initiation and elongation. Although elevated levels of SRSF2 are associated with advanced stages of lung adenocarcinoma (LUAD), the mechanisms connecting SRSF2 to lung tumor progression remain unknown. We show that SRSF2 overexpression increases global transcription and replicative stress in LUAD cells, which correlates with the production of DNA damage, notably double-strand breaks (DSBs), likely resulting from conflicts between transcription and replication. Moreover, SRSF2 regulates DNA repair pathways by promoting homologous recombination and inhibiting nonhomologous end joining. Mechanistically, SRSF2 interacts with and enhances MRE11 (meiotic recombination 11) recruitment to chromatin, while downregulating 53BP1 messenger RNA and protein levels. Both events are likely contributing to SRSF2-mediated DNA repair process rerouting. Lastly, we show that SRSF2 and MRE11 expression is commonly elevated in LUAD and predicts poor outcome of patients. Altogether, our results identify a mechanism by which SRSF2 overexpression promotes lung cancer progression through a fine control of both DSB production and repair. Finally, we show that SRSF2 knockdown impairs late repair of ionizing radiation-induced DSBs, suggesting a more global function of SRSF2 in DSB repair by homologous recombination.

1 October 2024 in Life Science Alliance
Verified
Journal Article
Open access
PDF file
SGSylvie Gazzeri
Sylvie Gazzeri
NZNadiia Zubchuk
Nadiia Zubchuk
EMElodie Montaudon
Elodie Montaudon
FNFariba Nemati
Fariba Nemati
SHSarah Huot-Marchand
Sarah Huot-Marchand
BEBeatrice Eymin
Beatrice Eymin
Despite initial high response rates to first-line EGFR TKI, all non–small-cell lung cancer (NSCLC) with EGFR-activating mutation will ultimately develop resistance to treatment. Identification of resistance mechanisms is critical to adapt treatment and improve patient outcomes. Here, we show that aPPP3CBtranscript that encodes full-length catalytic subunit 2B of calcineurin accumulates in EGFR-mutant NSCLC cells with acquired resistance against different EGFR TKIs and in post-progression biopsies of NSCLC patients treated with EGFR TKIs. Neutralization ofPPP3CBby siRNA or inactivation of calcineurin by cyclosporin A induces apoptosis in resistant cells treated with EGFR TKIs. Mechanistically, EGFR TKIs increase the cytosolic level of calcium and trigger activation of a calcineurin/MEK/ERK pathway that prevents apoptosis. Combining EGFR, calcineurin, and MEK inhibitors overcomes resistance to EGFR TKI in both in vitro and in vivo models. Our results identify PPP3CB overexpression as a new mechanism of acquired resistance to EGFR TKIs, and provide a promising therapeutic approach for NSCLC patients that progress under TKI treatment.

1 September 2018 in Experimental Cell Research
Verified
Journal Article
Closed access
ABAnais Beaumont
Anais Beaumont
DDDelphine Dayde
Delphine Dayde
AHAnne-Sophie Hatat
Anne-Sophie Hatat
CBCeline Barrial
Celine Barrial
PPPascal Perron
Pascal Perron
SGSylvie Gazzeri
Sylvie Gazzeri